3rd International AIDS Society Conference on HIV Pathogenesis and Treatment Rio de Janeiro - July 24 - 27, 2005

HIV-1 DRUG RESISTANCE IN CHINA: NATION-WIDE SURVEY AND ANALYSIS OF IMPACTING FACTORS IN THE NATIONAL ARV TREATMENT PROGRAM

IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: Abstract No. TuPp0302

Xing H.¹, Jiang S.¹, Si X.¹, Cheng H.¹, Shang H.², Li J.³, Kang L.⁴, Zhong P.⁴4, Shao Y.^1
1National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China, ²China Medical University, Shenyang, China, ³Chinese Academy of Military Medical Sciences, Beijing, China, ⁴Shanghai Center for Disease Control and Prevention, Shanghai, China

OBJECTIVE: To evaluate China’s ART program and provide HIV DR monitoring for the patients under HAART.

METHODS: Random sampling is applied to HIV-1 infected subjects with and without ART treatment. The subjects’ epidemiological data were collected and blood tested for viral load, CD4 count, and HIV DR genotyping by sequencing. The sequencing data is analyzed and scored based on the Stanford HIV drug resistance database.

RESULTS: In 2002, 2% medium and low resistance and no high resistance HIV DR related mutations were found in 200 HIV infected people from 20 provinces before ART program start. In 2004 study, very low background of 3.0% medium and low resistance and 1.2% high resistance HIV DR related mutations were found in 665 HIV positive drug naïve patients. Among patients in government treatment program using 4 regimens (average 8 month treatment), the best viral control rate of 95.3% (undetectable viral load) was achieved by AZT/3TC/NVP (N=41), followed by 70.8% by D4T/DDI/EFV (N=24), 65.5% by D4T/DDI/NVP (N=220) and 49.4% by AZT/DDI/NVP (N=81). HIV DR-related mutation was more frequently detected in individuals with using D4T/DDI/NVP and AZT/DDI/NVP (24.1% and 17.6% respectively) than in individuals using AZT/3TC/NVP and D4T/DDI/EFV (2.4% and 0.0% respectively). Logistic analysis showed the emerging DR-related mutation is positively correlated with the failure of viral control and the length of treatment. Emergence of multi-DR-related mutation was mainly found in ones adherent to one regimen and in subjects dropping out from ART therapy (19.2 % and 18.0% respectively).

DISCUSSIONS: The frequency of HIV DR-related mutation is very low in drug naïve HIV-1 infected subjects in China. The regimens of AZT/3TC/NVP and D4T/DDI/EFV are better than AZT/DDI/NVP and D4T/DDI/NVP measured by viral control and inhibition of HIV DR-related mutations. The emergence of DR-related mutation was the cause of ART treatment failure.

Download PDF of this abstract.

050724
Clinical | TuPp0302 | Hui Xing
4.1 652 4.1 Resistance surveillance

Copyright © 2005 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.